Loading...
Immunome Q4 2024 Earnings Report
Immunome reported its full year 2024 financial results and provided a business update.
Key Takeaways
Immunome reported a net loss of $292.963 million for the full year ended December 31, 2024. The company's cash, cash equivalents, and marketable securities totaled $217.3 million as of December 31, 2024, and its cash runway is expected to extend into 2027. Key pipeline updates include topline data for the Phase 3 RINGSIDE study of varegacestat expected in the second half of 2025, the first patient dosed in the Phase 1 clinical trial for IM-1021, and an IND submission for IM-3050.
Topline data for Phase 3 RINGSIDE study of varegacestat in progressing desmoid tumors expected in second half of 2025.
First patient dosed in Phase 1 clinical trial evaluating IM-1021, a ROR1-targeted ADC.
IND submitted in March 2025 for IM-3050, a FAP-targeted radioligand therapy, with a clinical trial anticipated in the second half of 2025.
Projected cash runway extends into 2027, supported by a $172.5 million public offering in January 2025.
Immunome
Immunome
Immunome Revenue by Segment
Revenue by Segment
Collaboration Revenue
CapyFin.com Forward Guidance
Immunome anticipates several key clinical milestones in 2025, including topline data for the RINGSIDE trial and initiation of a Phase 1 clinical trial for IM-3050. The company's cash runway is projected to extend into 2027.
Positive Outlook
- Topline data for Phase 3 RINGSIDE study of varegacestat expected in second half of 2025.
- Anticipated initiation of a Phase 1 clinical trial for IM-3050 in the second half of 2025.
- Projected cash runway extends into 2027, providing financial stability.
- Multiple programs now in clinical development, indicating pipeline advancement.
- Three additional novel ADCs (IM-1617, IM-1335, IM-1340) are in IND-enabling manufacturing.
Challenges Ahead
- Clinical trial data may not be predictive of future clinical data.
- Regulatory approvals for programs and product candidates may be delayed or subject to unanticipated conditions.
- Programs and product candidates may fail to achieve their intended endpoints.
- Uncertainties related to capital requirements and cash runway.
- Ability to grow and advance pipeline and successfully execute business plan is subject to risks.